Red and Processed Meats

According to the World Health Organization (WHO), consumption of red meats such as beef, pork, and lamb, as well as processed meats like ham, bacon, salami, and hot dogs, is linked to increased cancer risk. These meats are classified as Group 1 carcinogens because they contain specific chemicals—either naturally occurring or added during processing—that can promote cancer development. These substances, including certain nitrates, nitrites, and heterocyclic amines formed during cooking, can contribute to mutations in DNA, thereby increasing the risk of melanoma and other cancers. For individuals battling melanoma, reducing or eliminating these meats from their diet is highly recommended to decrease carcinogenic load and support treatment efficacy.

Sugary Foods and Sweets

Sweet treats, such as candies, pastries, and desserts, although tempting, offer minimal nutritional benefits and can negatively impact overall health. High sugar intake has been associated with increased inflammation and immune system suppression, which can hinder the body's ability to fight cancer cells. Moreover, excessive sugar consumption can interfere with the effectiveness of therapeutic interventions by creating a glucose-rich environment that tumors can exploit. Patients with melanoma are strongly advised to limit sweets and prefer nutrient-dense foods to bolster their body's defenses during treatment and recovery.

In addition to dietary modifications, patients should consider incorporating certain medications under medical supervision to enhance their treatment outcomes. Consultation with healthcare professionals is crucial before starting any pharmacological intervention.

OPDIVO® (nivolumab)

OPDIVO® (nivolumab) is an FDA-approved immunotherapy drug indicated for treating advanced melanoma, particularly when the cancer has spread beyond the primary site and surgery is not an option. It works by blocking PD-1, a protein that cancer cells use to evade immune detection, thereby bolstering the immune system's ability to target and destroy melanoma cells. Beyond melanoma, OPDIVO® has shown effectiveness against certain lung, bladder, and kidney cancers, making it a versatile option for cancer management.

YERVOY® (ipilimumab)

YERVOY® (ipilimumab) is another immunotherapeutic agent used in treating melanoma, especially in cases where the disease has metastasized or recurred after initial treatment. It helps stimulate the immune response by inhibiting CTLA-4, another immune checkpoint. This medication is suitable for adult patients and children below 12 years old. When combined with other treatments like nivolumab, it can improve long-term survival rates and decrease the likelihood of recurrence after surgical removal of affected lymph nodes.

It is important to remember that both OPDIVO® and YERVOY® should only be used under strict medical supervision. Their administration, dosage, and potential side effects need careful consideration and regular monitoring by healthcare providers.